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Abstract
Background: Use of phenacetin and other analgesic and non-steroidal anti-inflammatory drugs
(NSAIDs) potentially influences bladder cancer incidence, but epidemiologic evidence is limited.
Methods: We analyzed data from 376 incident bladder cancer cases and 463 controls from a
population-based case-control study in New Hampshire on whom regular use of analgesic drugs
and NSAIDs was obtained. Odds ratios and 95% confidence intervals were computed using logistic
regression with adjustment for potentially confounding factors. Separate models by tumor stage,
grade and TP53 status were conducted.
Results: We found an elevated odds ratio (OR) associated with reported use of phenacetin-
containing medications, especially with longer duration of use (OR >8 years = 3.00, 95% confidence
interval (CI) = 1.4–6.5). In contrast, use of paracetamol did not relate overall to risk of bladder
cancer. We also found that regular use of any NSAID was associated with a statistically significant
decrease in bladder cancer risk (OR = 0.6, 95% CI = 0.4–0.9), and specifically use of aspirin. Further,
the association with NSAID use was largely among invasive, high grade and TP53 positive tumors.
Conclusion: While these agents have been investigated in several studies, a number of questions
remain regarding the effects of analgesic and NSAID use on risk of bladder cancer.
Background
Bladder cancer is the 4th most common cancer in men and
the 10th in women [1]. While the main risk factor for blad-
der cancer is tobacco smoking, other important risk fac-
tors include certain occupational exposures such as
aromatic amines and PAHs (polyaromatic hydrocarbons),
exposure to water chlorination by-products [2], condi-
tions causing chronic inflammation of the urological epi-
thelium (e.g., infestation by Schistosoma haematobium) [2],
and use of the immunosuppressant cyclophosphamide
[3].
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There is limited, however intriguing evidence on the
effects of other drugs on bladder cancer risk, particularly
analgesics and anti-inflammatory drugs (See additional
file 1). Phenacetin, (N-(4-ethoxyphenyl) acetamide), an
analgesic drug, was classified by the International Agency
for Research on Cancer (IARC) in 1987 as being probably
carcinogenic to humans (Group 2A) and analgesic mix-
tures containing phenacetin as being carcinogenic (Group
1) [4]. Two epidemiologic studies of bladder cancer
included in the IARC report indicated an excess risks of
two- to over six-fold associated with use of phenacetin
containing drugs [[5,6], additional file 1]. One additional
study found a four-fold increased risk of bladder cancer
among phenacetin abusers [[7], additional file 1]. How-
ever, these were relatively small studies, and were not able
to demonstrate dose-related effects. While subsequent
studies, based on larger samples, are less clear [8-11],
most suggest an elevated risk (see additional file 1).
Although phenacetin has been discontinued in the US
since the 1980s, whether users of phenacetin remain at
increased risk of bladder cancer is not known as the
latency period is potentially longer than two decades [12].
Further, phenacetin's metabolite paracetamol (also
known as acetaminophen) also is related to an enhanced
risk of renal cancer [9,11,13-19]. While some studies of
bladder cancer found evidence of an elevated risk associ-
ated with heavy use of paracetamol, the majority did not,
and some suggested an overall decreased risk
[[6,8,10,11,13-15,19], additional file 1]. Studies to date
on NSAIDs use and bladder cancer risk are mixed [8,20-
25]. The largest of these found evidence of a reduction in
bladder cancer risk (OR = 0.63) with greater than 1242
grams of aspirin use and greater than or equal to 168
grams of acetic acids (OR = 0.65) [8], whereas a study, per-
formed on a general practitioner database in the UK (n =
1041), found no relation between any type of NSAID use
and risk of bladder cancer. As yet, there are limited data on
the effect of analgesics and NSAIDs on the incidence of
specific clinical, histopathologic or molecular types of
bladder cancer. Thus, in light of the currently inconclusive
evidence on the potential impact of analgesic and anti-
inflammatory drugs on bladder cancer occurrence, we
assessed lifetime use of these drugs in relation to bladder
cancer incidence in a population-based case-control
study. We further specifically evaluated associations with
stage, histologic grade and TP53 overexpression of the
tumor.
Methods
Study group
Through the New Hampshire State Department of Health
and Human Services' rapid reporting Cancer Registry, we
identified newly diagnosed cases of bladder cancer among
New Hampshire residents, aged 25–74 years during the
July 1, 1998 to December 31, 2001 period. For efficiency,
we shared a control group with a study of non-melanoma
skin cancer covering a diagnostic period of July 1, 1997 to
March 30, 2000. Controls less than 65 years of age were
selected using population lists obtained from the New
Hampshire Department of Transportation. Controls 65
years of age and older were chosen from data files pro-
vided by the Centers for Medicare & Medicaid Services
(CMS) of New Hampshire.
We conducted standardized in-person interviews with
study participants to obtain information on demographic
traits, use of tobacco (including frequency, duration and
intensity of cigarette smoking), alcohol, and other expo-
sures. We requested the original paraffin-embedded
tumor specimen for histopathology re-review by the study
pathologist who classified tumors according to WHO
ISUP criteria. Of the 342 cases with evaluable pathology,
327 (96%) were deemed cancerous by the study patholo-
gist. Due to the high concordance rates, we classified sub-
jects based on the original pathologist's diagnosis;
whereas tumor morphology, extent of disease, and grade
were based on the standardized histopathology re-review.
Immunohistochemical analysis of the tumors was per-
formed for TP53 and scored for intensity and percent of
tumor cells staining positively, as described previously
[26]. We obtained informed consent from each partici-
pant and all procedures and used study materials
approved by the Committee for the Protection of Human
Subjects at Dartmouth College.
Drug use assessment
Subjects were asked if they used a pain medication at least
four times a week for one month or longer prior to the ref-
erence date (diagnosis date of the cases and a comparable
date randomly assigned to the controls). Those who
responded positively were asked the brand names of each
medication they took, and for each medication, the age
began and stopped, total duration of use and the condi-
tion for which the drug was prescribed. Those who
responded that they did not use pain medications at the
specified frequency were considered non-users.
Brand names were recoded into active ingredients based
on a drug matrix that took into account variations in the
composition of the drugs over time, and specifically
addressed the exact years of withdrawal/substitution of
phenacetin from the formulation. Past editions of the
Physician Desk Reference ® were used as the main source
of information on drug composition to generate the
matrix. Whenever necessary, a variety of other sources
were used, such as direct contact with pharmaceutical
companies, documents from regulatory agencies and oth-
ers. Drug categories considered for the analysis were:
phenacetin, paracetamol, any NSAID (including aspirin,BMC Urology 2007, 7:13 http://www.biomedcentral.com/1471-2490/7/13
Page 3 of 9
(page number not for citation purposes)
ibuprofen, diclofenac and any other drug generally
included in this category), aspirin, and ibuprofen.
Statistical analysis
We computed ORs and their 95% confidence intervals for
bladder cancer risk for the studied drugs using logistic
regression with those who responded that they did not
use the pain medications at all or with the specified fre-
quency as the reference category. Risk estimates were
adjusted by age in quintiles according to the age distribu-
tion among the controls: (<52, 52 to 61, 62 to 67, 68 to
71, and >71 years), sex and smoking status (never, former,
current). We further assessed the possibility that educa-
tion, as a marker of socioeconomic status, could act as a
potential confounder but the inclusion of this variable did
not appreciably influence our results and therefore was
not included in our final models.
To distinguish the effects of the specific types of NSAIDs
and analgesic drugs, we used two models. One, the
"adjusted model", simultaneously included each of the
drug categories (i.e., phenacetin, paracetamol, aspirin,
ibuprofen and the rest of NSAIDs with or without aspirin
and/or ibuprofen) and the other, the "exclusive use"
model, included subjects that had only used one specific
type of pain medication. Duration was classified accord-
ing to tertiles of control distribution for each drug. Tests
for trend were performed by including a single term for
categorical exposure variables in logistic regression mod-
els using non-users as the reference category.
Further, we examined a model in which the drug use var-
iables excluded the year prior to the reference date in
order to assess the possibility of drug use consequent to
undiagnosed tumor symptoms. In addition to evaluating
all bladder cancers combined, we evaluated risks by extent
of disease (noninvasive versus invasive), for noninvasive
tumors, grade (low grade versus high grade), and TP53
intensity (<3 versus 3+). In the analysis of TP53 intensity,
we assessed whether further adjustment by stage or grade
affected the results. We did not find evidence of such
effects, and thus, did not include stage or grade in the final
models of TP53 status. The statistical package SAS v9.1
was used for all the analyses.
Results
Associations with medication use
Of the 472 potentially eligible cases we contacted, 398
(84%) took part in the study, and from 376 (94%) of
these, we obtained history of pain medication use. Of the
694 potential controls we contacted, 526 (76%) took part
in the study, and from 463 (88%) of these, we obtained
history of pain medication use. Subjects were mainly Cau-
casians and more than half were men (Table 1). More
cases than controls were over age 60 years, former or cur-
rent smokers, and did not have education beyond high
school (Table 1). Overall, 42% of cases and 45% of con-
trols reported regular use of a pain medication. Among
controls, 8% were regular users of phenacetin (4% of
women and 10% of men), 13% of paracetamol (18% of
women and 9% of men), 27% of aspirin (20% of women
and 32% of men), and 13% of ibuprofen (15% of women
and 11% of men). Of the histologically reviewed cancers,
Table 1: Selected characteristics of bladder cancer cases 
andcontrols from New Hampshire
Selected Characteristics Cases Controls
Total Subjects N (%) 398 (100) 526 (100)
Sex
Women 107 (27) 220 (42)
Men 291 (73) 306 (58)
Racea
White 379 (98) 513 (99)
Other 8 (2) 5 (1)
Age (Years)
≤ 51 57 (14) 106 (20)
52–61 108 (27) 123 (23)
62–67 90 (23) 112 (21)
68–71 89 (22) 103 (20)
>71 54 (14) 82 (16)
Highest Level of Educational Attainmenta
≤ High school 204 (53) 239 (46)
> High school 182 (47) 281 (54)
Cigarette Smokinga
Never 66 (17) 193 (37)
Former 195 (50) 243 (47)
Current 129 (33) 85 (16)
Amount Smoked (cigarettes/day)
≤ 12 41 (13) 90 (31)
12–20 132 (43) 119 (41)
>20 136 (44) 84 (29)
WHO-ISUP classificationb
Carcinoma in situ 18 (6) -
Papilloma 1 (0)
Papillary neoplasm of low malignant 
potential
84 (26) -
Papillary carcinoma, low grade 112 (34) -
Papillary carcinoma, high grade 74 (23) -
Other 38 (13) -
Tumour gradeb,c
Grade 1 145 (47) -
Grade 2 61 (20) -
Grade 3 103 (33) -
Tumour stageb
Superficial 216 (66) -
Invasive 93 (28) -
In situ 18 (6) -
a 8 controls and 11 cases had no race information, 6 controls and 12 
cases had no education information, 5 controls and 8 cases had no 
smoking information
b Restricted to individuals with confirmed cancers on histopathology 
reviewed (n = 327).
c Grade determinations exclude in situ lesions (n = 18).BMC Urology 2007, 7:13 http://www.biomedcentral.com/1471-2490/7/13
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66% percent were superficial and noninvasive, 6% were in
situ carcinomas, and 28% were invasive.
Bladder cancer cases reported regular phenacetin use more
frequently than control subjects (Table 2; OR = 2.2, 95%
CI = 1.3–3.8). The odds ratio associated with phenacetin
use was highest among those with longer duration of use
(OR>8 yrs = 3.0, 95% CI = 1.4–6.5), although even short
term users (4 years or less) had an increased risk (OR≤4 yrs
= 2.2, 95% CI = 1.0–4.7) (P for trend = 0.005). We were
unable to fit the exclusive use model for phenacetin
because there were no exclusive users. In contrast, regular
paracetamol use was not related to any statistically signif-
icant association with bladder cancer in the adjusted (OR
= 0.7, 95% CI = 0.4–1.2) or exclusive use (OR = 0.8, 95%
CI = 0.5–1.6) models (Table 2).
NSAID use was associated with a reduced risk of bladder
cancer (Table 3; adjusted model OR = 0.6, 95%CI = 0.4–
0.9 and exclusive use model OR = 0.6, 95%CI = 0.4–0.9).
The association with NSAIDs overall was largely due to
aspirin (adjusted model OR = 0.6, 95%CI = 0.4–0.9 and
exclusive model OR = 0.5, 95%CI = 0.3–0.8) (Table 3).
While the crude prevalence rate of aspirin use was higher
among cases than controls, a higher proportion of aspirin
users also consumed phenacetin. Thus, lack of adjustment
for phenacetin resulted in an odds ratio closer to unity
(OR = 0.9; 95% CI = 0.7–1.3).
Regular ibuprofen use was unrelated to risk of bladder
cancer in the adjusted model (OR = 0.8, 95%CI = 0.5–1.2)
and exclusive use model (OR = 0.9, 95%CI = 0.5–1.6).
Exclusion of drugs used in the year prior to the reference
date did not materially alter the risk estimates but com-
promised the statistical power of the analysis (data not
shown).
We indirectly assessed the effect of dose of aspirin by
using the condition for which aspirin was prescribed as a
proxy. In general, aspirin is prescribed for coronary heart
disease prevention at lower doses (i.e., ≤ 150 mg/day)
than for inflammatory or painful conditions (i.e., ≥ 325
mg bid or tid). When we stratified by condition we did not
find any differences in the risk estimates i.e., among aspi-
rin exclusive users the odds ratio was 0.5 (95%CI = 0.3–
0.9) for cardiovascular disease and 0.5 (95%CI = 0.2–1.3)
for other conditions.
Stratification by cell type, stage and grade
When we restricted the analysis of the effect of drugs to
transitional cell carcinomas, excluding squamous cell car-
cinomas (n = 2), small cell carcinoma (n = 2), adenocar-
cinomas (n = 1), and others (n = 13), results remained
unchanged (data not shown). Exclusion of papillary
urothelial neoplasia of low malignant potential (n = 84),
also yielded similar results for all drug use categories
except everusers of phenacetin had a slightly higher blad-
der cancer risk (OR = 2.6, 95%CI = 1.5–4.6) without these
cases.
Table 2: Odds ratios (95% confidence intervals) for bladder cancer among regular users of phenacetin and paracetamol, with 
adjustment for other drugs, and among exclusive users.
Drug use Adjusted Modela Exclusive Use Modelb
Controls N(%) Cases N(%) OR (95%CI)c Controls N(%) Cases N(%) OR (95%CI)c
Phenacetin
Never 421 (92.3) 313 (85.5) 1.0 (reference)
Ever 35 (7.7) 53 (14.5) 2.2 (1.3–3.8)
Duration of used
≤ 4 yrs 14 (3.1) 22 (6.0) 2.2 (1.0–4.7)
4–8 yrs 9 (2.0) 6 (1.6) 1.1 (0.4–3.5)
>8 yrs 12 (2.6) 25 (6.8) 3.0 (1.4–6.5)
P for linear trende 0.005
Paracetamol
Never 398 (87.3) 335 (91.5) 1.0 (reference) 249 (89.6) 211 (90.9) 1.0 (reference)
Ever 58 (12.7) 31 (8.5) 0.7 (0.4–1.2) 29 (10.4) 21 (9.1) 0.8 (0.5–1.6)
Duration of used
≤ 4.5 yrs 19 (4.2) 12 (3.3) 0.9 (0.4–1.9) 12 (4.3) 8 (3.4) 0.8 (0.3–2.0)
4.5–16 yrs 19 (4.2) 13 (3.6) 0.9 (0.4–1.9) 10 (3.6) 9 (3.9) 0.9 (0.4–2.5)
>16 yrs 20 (4.4) 6 (1.6) 0.4 (0.2–1.2) 7 (2.5) 4 (1.7) 0.8 (0.2–3.1)
P for linear trende 0.116 0.672
a Model adjusted by age, sex, number of cigarettes smoked per day, and use of other NSAIDs and analgesics
b Model adjusted by age, sex, and number of cigarettes smoked per day
c Excluded 3 subjects missing number of cigarettes smoked per day.
d Based on tertile of duration of use among controls. No medication use is referent.
e Tests for trend were performed by including a single term for categorical duration of medication use using non-users as the reference category.BMC Urology 2007, 7:13 http://www.biomedcentral.com/1471-2490/7/13
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In the analysis stratified by tumor phenotype, we found a
stronger  inverse association with NSAID use for invasive,
high grade non-invasive and TP53 positive tumors (Table
4). There were no consistent patterns by stage, grade or
TP53 status with the other drugs.
Discussion
Our findings suggest that regular use of NSAIDs, in partic-
ular aspirin, related to a lower risk of this malignancy. The
association appeared strongest for invasive, high grade
noninvasive and TP53 positive tumors. Also, our findings
provide further evidence of an increased risk of bladder
cancer among users of phenacetin-containing drugs, and
additionally, suggest that risk is greatest among long term
users.
Case-control studies like ours have the potential for recall
bias. To enhance recall we showed lists of commonly used
anti-inflammatory and analgesic medications. One con-
cern is that the prevalence of recalled phenacetin use may
be lower for recent studies because the drug was with-
drawn from the market nearly two decades ago and recall
of past NSAID use decreases with time since last use [27].
Arguing against the presence of recall bias is that the prev-
alence rates of analgesic and anti-inflammatory drug use
in our study were similar to those of other studies con-
ducted in the United States, Northern Europe and Aus-
tralia [5,8,11]. If subjects had been aware of the relation
between phenacetin and urothelial cancers, recall bias
could, at least, partly explain the increased risk seen for
this drug. It is worth noting, however, that phenacetin was
withdrawn from the market because of its association
with interstitial nephritis, not because of an increased risk
of cancer. Thus, bladder cancer patients would probably
not relate their cancer to their use of phenacetin in the
past. Finally, people tend to remember the brands of the
phenacetin-containing anti-flu medications (e.g., Repan,
Norgesic, Phenaphen, Fiorinal and Darvon compound),
more than the actual ingredients because these anti-flu
preparations usually included a combination of analge-
sics (i.e., phenacetin antihistamines, decongestants, and
other ingredients). Nevertheless, we cannot rule out the
possibility that some degree of recall bias might have
affected our results. For other analgesics and NSAIDs, we
Table 3: Odds ratios (95% confidence intervals) for bladder cancer among regular users of NSAIDs, with adjustment for other drugs, 
and among exclusive users.
Drug use Adjusted modela Exclusive use modelb
Controls N(%) Cases N(%) OR (95%CI)c Controls N(%) Cases N(%) OR (95%CI)c
All NSAIDs
Never 278 (61.0) 232 (63.4) 1.0 (reference) 249 (68.0) 211 (74.6) 1.0 (reference)
Ever 178 (39.0) 134 (36.6) 0.6 (0.4–0.9) 117 (32.0) 72 (25.4) 0.6 (0.4–0.9)
Duration of used
≤ 4 yrs 61 (13.4) 47 (12.8) 0.7 (0.4–1.1) 46 (12.6) 25 (8.8) 0.6 (0.4–1.1)
4–10 yrs 58 (12.7) 37 (10.1) 0.5 (0.3–0.8) 35 (9.6) 23 (8.1) 0.6 (0.3–1.1)
>10 yrs 59 (12.9) 50 (13.7) 0.7 (0.4–1.1) 36 (9.8) 24 (8.5) 0.6 (0.4–1.1)
P for linear trende 0.020 0.029
Aspirin
Never 333 (73.0) 263 (71.9) 1.0 (reference) 249(78.3) 211(84.4) 1.0 (reference)
Ever 123 (27.0) 103 (28.1) 0.6 (0.4–0.9) 69(21.7) 39(15.6) 0.5 (0.3–0.8)
Duration of used
≤ 4 yrs 43 (9.4) 32 (8.7) 0.5 (0.3–0.9) 27(8.5) 10(4.0) 0.4 (0.2–0.8)
4–9 yrs 41 (9.0) 24 (6.6) 0.3 (0.2–0.6) 21(6.6) 12(4.8) 0.5 (0.2–1.0)
>9 yrs 39 (8.6) 47 (12.8) 0.9 (0.5–1.5) 21(6.6) 17(6.8) 0.7 (0.4–1.4)
P for linear trende 0.114 0.038
Ibuprofen
Never 399 (87.5) 332 (90.7) 1.0 (reference) 257 (88.3) 214 (89.5) 1.0 (reference)
Ever 57 (12.5) 34 (9.3) 0.8 (0.5–1.2) 34 (11.7) 25 (10.5) 0.9 (0.5–1.6)
Duration of used
≤ 3 yrs 22 (4.8) 15 (4.1) 0.9 (0.5–1.9) 11 (3.8) 11 (4.6) 1.5 (0.6–3.7)
3–10 yrs 16 (3.5) 8 (2.2) 0.5 (0.2–1.3) 10 (3.4) 7 (2.9) 0.7 (0.3–2.0)
>10 yrs 19 (4.2) 11 (3.0) 0.8 (0.4–1.8) 13 (4.5) 7 (2.9) 0.7 (0.3–1.8)
P for linear trende 0.244 0.484
a Model adjusted by age, sex, number of cigarettes smoked per day, and use of other NSAIDs and analgesics
b Model adjusted by age, sex, and number of cigarettes smoked per day
c Excluded 3 subjects missing number of cigarettes smoked per day.
d Based on tertile of duration of use among controls. No NSAID use is referent.
e Tests for trend were performed by including a single term for categorical duration of NSAID use using non-users as the reference category.BMC Urology 2007, 7:13 http://www.biomedcentral.com/1471-2490/7/13
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would not anticipate differential recall (i.e., between cases
and controls) because these drugs are not generally per-
ceived as modifiers of bladder cancer risk. Moreover, the
effects of the various drugs were not all in one direction as
would be expected in the presence of recall bias.
While we do not suspect differential misclassification (i.e.,
due to recall bias), non-differential misclassification likely
exists in our data. We attempted to minimize this by
defining drug use as frequent use (e.g., four times per
week during a month or more). By doing this, the "non-
users" category included subjects who could have used the
drugs but did not fulfill our user definition. Such misclas-
sification likely would lead to an underestimate of the
effects.
We further need to consider the possibility of selection
bias, i.e, that non-participants or those on whom we
lacked drug use information differed from participants in
ways that were not accounted for in the analysis. Overall
participants and non-participants were generally similar
according to factors we were able to evaluate: age, sex and
urban residence (data not shown). Lack of adjustment for
occupational history, exposure to water chlorination
byproducts or other factors could potentially have biased
our results. However, high risk occupational exposures or
water chlorination exposure are unlikely to be related to
the use of analgesics or NSAIDs, and adjustment for these
factors did not affect the relation between medication use
and risk of bladder cancer in a case-control study from
Spain [28]. In our study, adjustment for educational level,
did not influence our results. Moreover, if non-partici-
pants were more or less likely to use analgesics or NSAIDs,
the resultant bias would be predicted to occur in a similar
direction for all drugs (as with recall bias), which did not
appear to be the case in our data. Perhaps a more impor-
tant limitation of our analysis is lack of statistical preci-
sion, leaving chance as a possible explanation for our
results.
Knowledge of the effects of phenacetin on urinary cancers
largely derives from animal experiments and from studies
of renal cancers for which a causal association has been
established [4]. Relatively few epidemiologic studies have
examined phenacetin and bladder cancer with published
risk estimates ranging from 0.7 to 6.5 [[5,6,8,10,11], addi-
tional file 1]. Of the five prior studies conducted, only one
observed no increase in bladder cancer risk among phen-
acetin users [11]. Our data further support an etiologic
role of phenacetin in bladder cancer occurrence and they
further suggest that risk increases with duration of use.
Paracetamol is a metabolite of phenacetin, but it is
unclear whether paracetamol retains the carcinogenic
potential of its parent compound. In our study, paraceta-
mol was unrelated to bladder cancer risk. This agrees with
the published literature which is generally consistent with
no effect [6,8,10,11,13-15,19]. Paracetamol is not a
potent inhibitor of cyclooxygenase (COX), but may
inhibit NFkB, a transcription factor related to the inhibi-
tion of apoptosis [29], up-regulated in several cancers,
including bladder cancer [30]. Metabolism of paraceta-
mol results in a reactive metabolite (N-acetyl-P-benzoqui-
none imine (NAPQI)) that can form DNA adducts [31]
and cause liver and renal toxicity [32]. Thus, paracetamol,
in theory, could promote apoptosis through NFkB inhibi-
tion conferring protection against bladder cancer, or con-
versely, could act as a bladder carcinogen through
accumulation of DNA adducts from its toxic metabolite
NAPQI. Recent evidence also raises the possibility of a
role of genetic variation of paracetamol metabolizing
genes on bladder cancer susceptibility associated with
paracetamol use [28]. Further investigation of genetic var-
iation in the metabolic pathway of paracetamol and
Table 4: Odds ratios (95% confidence intervals) for bladder cancer among regular users of NSAIDs, with adjustment for other drugs – 
stratified by tumor invasion, tumor grade and TP53 IHC intensity.
Drug usea Invasion Noninvasive TP53 IHC Intensity
Noninvasive Invasive Low grade High grade <3 3+
OR (95%CI)b OR (95%CI)b OR (95%CI)b OR (95%CI)b OR (95%CI)b OR (95%CI)b
Phenacetin 2.4 (1.3–4.5) 2.2 (0.9–5.1) 2.2 (1.1–4.2) 4.3 (1.0–17.9) 2.0 (1.1–3.8) 2.7 (1.2–6.5)
Paracetamol 0.6 (0.3–1.1) 1.1 (0.5–2.2) 0.5 (0.2–0.9) 2.0 (0.6–6.4) 0.4 (0.2–0.8) 1.7 (0.8–3.5)
All NSAIDs 0.7 (0.4–1.0) 0.5 (0.3–1.0) 0.7 (0.5–1.1) 0.4 (0.1–1.4) 0.8 (0.5–1.2) 0.5 (0.3–0.9)
Aspirin 0.6 (0.3–1.0) 0.4 (0.2–0.9) 0.6 (0.4–1.0) 0.5 (0.1–1.8) 0.7 (0.4–1.1) 0.4 (0.2–0.9)
Ibuprofen 0.7 (0.4–1.3) 0.7 (0.3–1.6) 0.8 (0.4–1.4) 0.3 (0.0–2.3) 0.9 (0.5–1.6) 0.6 (0.2–1.4)
a Restricted to the 327 subjects having pathologic examination of tumor material and confirmation of diagnosis.
b Referent category is never use of NSAID medications. Model adjusted by age, sex, number of cigarettes smoked per day, and use of other NSAIDs 
and analgesics.BMC Urology 2007, 7:13 http://www.biomedcentral.com/1471-2490/7/13
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tumor phenotype in this and other populations may help
to clarify the anti-carcinogenic or carcinogenic potential
of paracetamol.
Aspirin and other NSAIDs are COX inhibitors (with vary-
ing isoenzyme affinities) and probably have alternative
targets of action (i.e., NF kappa B inhibition) that could
influence cancer occurrence [33]. COX-2 enzyme is over-
expressed in most bladder tumors [34], and it is the induc-
ible isoenzyme thought to promote carcinogenesis via
induction of anti-apoptotic, proangiogenic and other
tumorigenic stimuli and pathways involving the tumor
suppressor gene TP53 [35]. COX-2 expression has been
related to advanced bladder cancers, i.e., advanced stage
and high grade histology [36]. These findings are consist-
ent with the stronger association we observed with NSAID
use among those with more aggressive tumors and those
with TP53 alteration, suggesting that COX inhibition
could be especially relevant for these poorer prognosis
tumors. However, to our knowledge, no previously pub-
lished studies have evaluated this.
Among the commonly prescribed NSAIDs, aspirin and
ibuprofen are non-selective COX inhibitors, and
diclofenac is COX-2 selective [33]. Randomized clinical
trials assessing various NSAIDs for bladder cancer are cur-
rently underway, although results are still unavailable.
Low dose aspirin (100 mg every other day) for an average
of ten years did not lower bladder cancer incidence in the
Women's Health Study randomized controlled trial (with
27 cases in the treatment and 24 cases in the placebo
group) [37]. Our results generally are in agreement with a
large population-based study from southern California
[8] that observed a reduced bladder cancer risk particu-
larly among heavy users of aspirin (OR = 0.63, 95%CI =
0.43–0.92 for the highest tertile of cumulative dose).
However, other case-control studies have not reported a
relation between the use of aspirin and the risk of bladder
cancer [11,20]. Additionally, all prospective studies have
been null although based on a limited number of bladder
cancer events [21,23-25,38]. The most recent prospective
cohort study [23] found an increased mortality from blad-
der cancer in women that had been users of aspirin (RR =
12.31, 95%CI = 2.98–50.80), based on 15 bladder cancer
deaths, and no association in men. Use of bladder cancer
mortality rather than incidence as the endpoint further
complicates the interpretation of this and other studies as
bladder cancer carries a relatively favorable prognosis.
Thus, the potential role of aspirin on bladder cancer risk
is as yet unresolved.
Regarding non-aspirin NSAIDs, the southern California
study found a decreased bladder cancer risk among acetic
acid NSAIDs users, with a suggestion of a dose-response
effect (OR = 0.46, 95%CI = 0.21–1.03 for heaviest users).
A record linkage study from Denmark with 330 bladder
cancer cases, found that prescribed non-aspirin NSAIDs
slightly increased the risk of bladder cancer (OR = 1.2,
95%CI = 1.0–1.3), although no dose-response relation-
ship was observed [24]. Misclassification also is likely in
studies relying solely on prescription data as many com-
monly used NSAIDs do not require a prescription. Further
studies with a larger number of subjects may be able to
discriminate the effects of specific NSAIDs more clearly.
Conclusion
In conclusion, our data provide evidence that aspirin use
may be related to a decreased bladder cancer risk, particu-
larly for more advanced tumors and ones that contain
TP53 alterations. They confirm previous findings on an
increased risk of bladder cancer among users of phenace-
tin-containing medications, and additionally suggest that
the risk relates to duration of use. Bladder cancer is the
most common urologic malignancy in humans, and it
typically carries a favorable prognosis, but mortality and
morbidity, including a high risk of recurrence, remain
important public health concerns. While several studies
have investigated the role of NSAIDs and other analgesic
medications, many issues remain. In light of the chemo-
preventive effects of NSAIDs including aspirin for other
neoplasms, the possibility that they may reduce bladder
cancer incidence warrants further consideration. Studies
assessing the effect on bladder cancer prognosis are lack-
ing but would be of great interest.
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